title: A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.
authors.affiliation: Department of Urology, St. Ignatius Hospital, Breda, The Netherlands.
authors.forename: G A
authors.initials: GA
authors.lastname: Dijkman
authors.forename: F M
authors.initials: FM
authors.lastname: Debruyne
authors.forename: P
authors.initials: P
authors.lastname: Fernandez del Moral
authors.forename: J W
authors.initials: JW
authors.lastname: Plasman
authors.forename: J W
authors.initials: JW
authors.lastname: Hoefakker
authors.forename: J G
authors.initials: JG
authors.lastname: Idema
authors.forename: M
authors.initials: M
authors.lastname: Sykes
mesh_terms: D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D017273:Goserelin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D003692:Delayed-Action Preparations; D017273:Goserelin